Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also
co-infected with HCV. Thus, hemophiliacs represent an important population for studies of
the natural history of these chronic viral infections.
Moreover, the high rate of co-infection makes it an ideal group for assessing the
interaction between the viruses and the relationship between viral specific immune responses
and clinical progression.
Although the hemophiliac poulation is unique, co-infection by these chronic viral pathogens
is becoming increasingly common, particularly amongst intravenous drug users, who account
for approximately 25% of the HIV-1 epidemic in the United States.
The aim of this study is to determine if polymorphism in the promoter region of TH1 and Th2
cytokines are associated with (1) intracellular cytokines levels in CD4 + Tcells, (2) Human
Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) viral loads, and (3) clinical
progression of HIV1 to AIDS in hemophiliacs.
The current proposal will investigate host genetic factors related to HIV-1 and HCV
immunopathogenesis by studying children and adolescents enrolled in the Hemophilia Growth
and Development Study (HGDS).
This study is in collaboration with the principle investigators of the Hemophilia Growth and
Development Study (HGDS) as part of a grant "Pathogenesis of HIV and HCV in Hemophilia:
HGDS-3" with funding support by NIH/NICHD for the period 9/25/01 through 8/31/2005.
This multicenter, United States study represents a well-characterized, prospectively
followed cohort of HCV-infected hemophiliacs, of whom 207 are HIV-1 co-infected.
Enrollment of the hemophiliac cohort was completed between 3/89 and 6/90. The final
observation of the cohort (follow-up 16) was concluded during 7/98. No new samples or
clinical data will be collected on this population.
The LGD plays two roles in this project: (1) an administrative role overseeing the
withdrawal, handling, and transport of samples from the HGDS/LGD and central repositories at
the NCI-Frederick, and (2) a scientific role continuing investigations to determine the role
of host genetic factors in Th1 and Th2 immune response and regulation of HCV and HIV viral
Michael Dean, Ph.D.
National Cancer Institute (NCI)
United States: Federal Government
|University of Iowa||Iowa City, Iowa 52242|
|University of Oklahoma||Oklahoma City, Oklahoma 73190|
|Wayne State University Hutzel Hospital||Detroit, Michigan 48201|
|University of California, San Diego||La Jolla, California 92037-1709|
|NCI Frederick Cancer Research Center||Frederick, Maryland 21702-1201|
|University of Nebraska||Omaha, Nebraska 68198|
|Mt. Sinai Medical Center||New York, New York 10029|
|Cornell University||New York, New York 10021|
|Childrens Hospital, Los Angeles||Los Angeles, California 90054-0700|
|St. Vincent Hospital & Health Care Center||Indianapolis, Indiana 46260|
|Tulane University||New Orleans, Louisiana 70112-2699|
|Childrens Mercy Hospital||Kansas City, Missouri|
|Milton Hershey Medical Center||Hershey, Pennsylvania 17033-2390|
|University of Texas, Houston||Houston, Texas 77225|
|University of Texas, San Antonio||San Antonio, Texas 78229-3900|